Top-News
Werbung

Attraktive Knock-Outs auf Sanofi SA

Typ Hebel Bid / Ask WKN
Call
5,1 1,80 € / 1,81 €
SN5671
Call
10,5 0,86 € / 0,87 €
SU3B43
Typ Hebel Bid / Ask WKN
Put
4,9 1,86 € / 1,87 €
SH8FSC
Put
10,2 0,88 € / 0,89 €
SU0ZVW
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Sanofi SA
Pharmazeutika Frankreich

Sanofi SA News

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF
91,03 €
+0,91 €
+1,01%
10:49:03 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
1,25 Mrd.
Marktkapitalisierung *
112,65 Mrd. €
Streubesitz
82,52%
Index-Zugehörigkeit
Euro Stoxx 50
IR-Website
zur Website
*Stand: 25.04.2024
Weiter aufwärts? Long handeln - Jetzt mit Hebel 10,97: VV0D86
Werbung

Unternehmensmeldungen

19.10.23 - GlobeNewswire
Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
04.10.23 - GlobeNewswire
Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
01.12.22 - DGAP
Form 8.3 - The Vanguard Group, Inc.: Sanofi
The Vanguard Group, Inc. ( IRSH) Form 8.3 - The Vanguard Group, Inc.: Sanofi 01-Dec-2022 / 15:09 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS ...
28.04.22 - GlobeNewswire
Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1
Sanofi continues to deliver strong business EPS ( 1) growth driven by higher sales and improved margins in Q1
23.02.22 - GlobeNewswire
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine * Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- ...
04.02.22 - GlobeNewswire
Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D
Strong 2021 sales and business EPS (1) growth enabling increased investment in R&D
03.02.22 - GlobeNewswire
Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity
Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity
16.04.21 - DGAP
Morgan Stanley Europe SE: Stabilisation Notice
DGAP-News: Morgan Stanley Europe SE / Key word(s): Miscellaneous Morgan Stanley Europe SE: Stabilisation Notice 16.04.2021 / 16:35 The issuer is solely responsible for the ...
09.04.19 - DGAP
Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales
Hardman & Co Research Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales 09-Apr-2019 / 16:10 GMT/BST
21.01.19 - GlobeNewswire
Sanofi UK marketing authorisation granted for Sanofi Pasteur’s Trivalent Influenza Vaccine (Split Virion, Inactivated) High Dose▼(TIV High Dose)
Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) UK marketing authorisation granted for Sanofi Pasteur’s Trivalent Influenza Vaccine (Split Virion, Inactivated) ...
03.02.15 - GlobeNewswire
Sanofi : Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.
Sanofi : Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S. Sanofi and MannKind Announce Afrezza ® ,  the Only Inhaled Insulin, Now ...
15.02.11 - ots
The World Heart Federation, sanofi-aventis and Boehringer ...
The World Heart Federation, sanofi-​aventis and Boehringer Ingelheim Announce Collaboration on Worldwide AF Awareness Campaign Geneva (ots/PRNewswire) - The World Heart ...
05.11.10 - ots
Sanofi-aventis Partners in European Atrial Fibrillation ...
Sanofi-​aventis Partners in European Atrial Fibrillation Research Consortium Paris, November 5 (ots/PRNewswire) - Sanofi-​aventis announced today that it is a partner in a new ...
29.10.10 - ots
Covance und sanofi-aventis schliessen endgültiges ...
Covance und sanofi-​aventis schliessen endgültiges Übereinkommen für 10-jährige strategische Zusammenarbeit im Bereich F&E Princeton, New Jersey (ots/PRNewswire) - ...
26.10.10 - ots
Sanofi-aventis Initiates Phase III Study with Teriflunomide ...
Sanofi-​aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis Paris (ots/PRNewswire) - ...
30.09.10 - ots
Covance und Sanofi-Aventis unterzeichnen Vertrag über ...
Covance und Sanofi-​Aventis unterzeichnen Vertrag über 10-jährige Zusammenarbeit im F&E-Bereich Princeton, New Jersey (ots/PRNewswire) - Covance Inc. gab heute die ...
20.09.10 - ots
Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug ...
Sanofi-​aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes Paris (ots/PRNewswire) - Sanofi-​aventis ...
20.09.10 - ots
Sanofi-aventis: Investigational Compound Once-Daily ...
Sanofi-​aventis: Investigational Compound Once-​Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients With Type 2 Diabetes Paris ...
31.03.10 - ots
AgaMatrix und sanofi-aventis gehen weltweite Partnerschaft ...
AgaMatrix und sanofi-​aventis gehen weltweite Partnerschaft im Bereich Diabetes ein Salem, New Hampshire, March 31, 2010 (ots/PRNewswire) - AgaMatrix, Inc. und sanofi-​aventis ...
30.03.10 - ots
Sanofi-aventis: Multaq(R) Receives Positive Recommendation ...
Sanofi-​aventis: Multaq(R) Receives Positive Recommendation by NICE in New Appraisal Consultation Document Paris, March 30, 2010 (ots/PRNewswire) - Sanofi-​aventis ...

Newssuche

Videos

27.06.24 -3,89%
Technical Trading: 10yr T-Notes Long Chance
10yr T-Notes Long Typ: Turbo Open End WKN: JL04UJ Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »